These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33503944)

  • 1. How Do Pharmaceutical Companies Overcome a Corporate Productivity Crisis? Business Diversification into Medical Devices for Growth Potential.
    Euh Y; Lee D
    Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33503944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategic trends of pharmaceutical companies: A growth model through regional focus and inter-regional alliances.
    Nakashima A; Kodama K; Sengoku S
    Drug Discov Today; 2023 Jul; 28(7):103611. PubMed ID: 37164307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
    Kato M; Ishikawa H; Okuhara T; Kiuchi T
    Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public health and corporate social responsibility: exploratory study on pharmaceutical companies in an emerging market.
    Dănescu T; Popa MA
    Global Health; 2020 Dec; 16(1):117. PubMed ID: 33302949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategic management and organizational culture of medical device companies in relation to corporate performance.
    Park S; Kim HK; Lee HJ; Choi M; Lee M; Jakovljevic M
    J Med Econ; 2023; 26(1):781-792. PubMed ID: 37300440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring How and Why to Develop Patient-Centered Packaging: A Multiple-Case Study with Pharmaceutical Companies.
    Carli Lorenzini G; Olsson A
    Ther Innov Regul Sci; 2022 Jan; 56(1):117-129. PubMed ID: 34581997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digital Medical Information Services Delivered by Pharmaceutical Companies via WeChat: Qualitative Analytical Study.
    Ge Y; Yao D; Ung COL; Xue Y; Li M; Lin J; Hu H; Lai Y
    J Med Internet Res; 2023 Nov; 25():e43812. PubMed ID: 37976079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Financialization of the health sector in Brazil: theoretical and methodological challenges to the investigation of companies and business groups].
    Bahia L; Poz MD; Levcovitz E; Costa LS; Mattos LV; Andrietta LS; Monte-Cardoso A; Travassos C
    Cad Saude Publica; 2022; 38Suppl 2(Suppl 2):e00004420. PubMed ID: 36043615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corporate risk from extremist groups.
    Sancenito J
    J Bus Contin Emer Plan; 2018 Jan; 12(1):17-26. PubMed ID: 30126524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The Korean Pharmaceutical Industry and the Expansion of the General Pharmaceuticals Market in the 1950-1960s].
    Sihn KH
    Uisahak; 2015 Dec; 24(3):749-81. PubMed ID: 26819439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics, risk management and GMP standards of pharmaceutical companies in China.
    Chen H; Qin L; Jiang C; Qin M; Sun Y; Luo J
    Front Public Health; 2023; 11():1103555. PubMed ID: 36969675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of the Internet plus Drug Circulation Business Model Based on Value Chain.
    Liang L
    J Healthc Eng; 2021; 2021():6673649. PubMed ID: 33953898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human rights responsibilities of pharmaceutical companies in relation to access to medicines.
    Lee JY; Hunt P
    J Law Med Ethics; 2012; 40(2):220-33. PubMed ID: 22789042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of China's Vaccine Incidents on the Operational Efficiency of Biopharmaceutical Companies.
    Chai KC; Tao R; Chang KC; Yang Y
    Front Public Health; 2020; 8():93. PubMed ID: 32322567
    [No Abstract]   [Full Text] [Related]  

  • 17. Financial ties and conflicts of interest between pharmaceutical and tobacco companies.
    Shamasunder B; Bero L
    JAMA; 2002 Aug; 288(6):738-44. PubMed ID: 12169078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research and development productivity map: visualization of industry status.
    Shimura H; Masuda S; Kimura H
    J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early achievements of the Danish pharmaceutical industry-6 Pharmacia].
    Grevsen JV; Kruse E; Kruse PR
    Theriaca; 2014; (42):9-30. PubMed ID: 25816560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies.
    Ledley FD; McCoy SS; Vaughan G; Cleary EG
    JAMA; 2020 Mar; 323(9):834-843. PubMed ID: 32125401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.